By Colin Kellaher
Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription factor for autoimmune diseases.
Nurix on Wednesday said it received a $15 million license extension fee from Sanofi under its 2019 collaboration agreement, bringing the total amount the San Francisco clinical-stage biopharmaceutical company has received to date under the pact to $105 million.
Nurix said the new collaboration target is a central regulator of the inflammation response and is distinct from the companies' existing STAT6 degrader program.
Nurix said it remains eligible for up to $465 million in development, regulatory and commercial milestone payments per licensed program under its work with Sanofi, as well as royalties on future sales.
Shares of Nurix were recently up 3.1% to $10.79 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 02, 2025 07:33 ET (11:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。